think it’s being overlooked that monepatel is a potential solution to a range of neurodegenrative disorders not just MND. Pathway for Alzheimers is impacted via mTor pathway as supported below. Massive opportunities - PAA could be a game changer!
Slide 13
Souce: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335350/
Source: https://www.mdpi.com/1422-0067/20/3/728
Most excited about the Neurodegenerative preclinical results. Monepantel is a selective mTor inhibitor and reduces autophagy. This is the main driver of Parkinson’s and Alzheimers.
Ann: Singapore Healthcare Day Presentation, page-6
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $170.5K | 749.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34313 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 24444 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.010 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 22.0¢ | 246904 | ||
| Last updated 15.57pm 14/06/2024 ? | |||||
| PAA (ASX) Chart |